Yohei Tomita
Department of Ophthalmology
Boston Children's Hospital, Harvard Medical School
Yohei Tomita is a senior staff scientist at the ophthalmology department in Boston Children’s Hospital and a visiting instructor at the ophthalmology department in Keio University School of Medicine.
Dr. Tomita graduated in medicine from Shimane University in Japan. He completed his ophthalmology residency, retinal fellowship, and earned his Ph.D. at Keio University School of Medicine. Then he joined at Ophthalmology department at Harvard Medical School, Boston Children’s Hospital as a research fellow. He is the recipient of the Bert M. Glaser, MD Award for Innovative Research in Retina (2021), the Young Investigator Award (2020) in Japan Ophthalmology Society, and the Young Investigator Grant Award (2020) in Alcon Research Institute. He is also a review editor and a guest editor for several journals.
Dr. Tomita is also now developing a new instrument that can measure mitochondrial function in the retina in vivo using Raman spectroscopy as well as a similar instrument using microfluidics and Raman to interrogate mitochondrial function.
Dyslipidemia in retinal metabolic disorders.
EMBO molecular medicine 10, 2019 | Pubmed ID: 31486227
Long-Acting FGF21 Inhibits Retinal Vascular Leakage in In Vivo and In Vitro Models.
International journal of molecular sciences Feb, 2020 | Pubmed ID: 32054022
Targeting Neurovascular Interaction in Retinal Disorders.
International journal of molecular sciences Feb, 2020 | Pubmed ID: 32098361
Free fatty acid receptor 4 activation protects against choroidal neovascularization in mice.
Angiogenesis Aug, 2020 | Pubmed ID: 32140799
Pemafibrate Protects Against Retinal Dysfunction in a Murine Model of Diabetic Retinopathy.
International journal of molecular sciences Aug, 2020 | Pubmed ID: 32872333
Wnt signaling activates MFSD2A to suppress vascular endothelial transcytosis and maintain blood-retinal barrier.
Science advances 08, 2020 | Pubmed ID: 32923627
IGF1, serum glucose, and retinopathy of prematurity in extremely preterm infants.
JCI insight 10, 2020 | Pubmed ID: 33004691
PPARα Agonist Oral Therapy in Diabetic Retinopathy.
Biomedicines Oct, 2020 | Pubmed ID: 33086679
Vitreous metabolomics profiling of proliferative diabetic retinopathy.
Diabetologia 01, 2021 | Pubmed ID: 33099660
Fenofibrate Protects against Retinal Dysfunction in a Murine Model of Common Carotid Artery Occlusion-Induced Ocular Ischemia.
Pharmaceuticals (Basel, Switzerland) Mar, 2021 | Pubmed ID: 33799938
Retinal glial remodeling by FGF21 preserves retinal function during photoreceptor degeneration.
iScience Apr, 2021 | Pubmed ID: 33937726
Iris metastasis as the initial presentation of metastatic esophageal cancer diagnosed by fine needle aspiration biopsy: A case report.
Medicine Jun, 2021 | Pubmed ID: 34087906
Pemafibrate Prevents Retinal Dysfunction in a Mouse Model of Unilateral Common Carotid Artery Occlusion.
International journal of molecular sciences Aug, 2021 | Pubmed ID: 34502311
Updates on the Current Treatments for Diabetic Retinopathy and Possibility of Future Oral Therapy.
Journal of clinical medicine Oct, 2021 | Pubmed ID: 34682788
Myeloid lineage contributes to pathological choroidal neovascularization formation via SOCS3.
EBioMedicine Nov, 2021 | Pubmed ID: 34688035
Müller glial responses compensate for degenerating photoreceptors in retinitis pigmentosa.
Experimental & molecular medicine 11, 2021 | Pubmed ID: 34799683
Metabolism in Retinopathy of Prematurity.
Life (Basel, Switzerland) Oct, 2021 | Pubmed ID: 34832995
PPARα Modulation-Based Therapy in Central Nervous System Diseases.
Life (Basel, Switzerland) Nov, 2021 | Pubmed ID: 34833044
Retinal Degeneration in a Murine Model of Retinal Ischemia by Unilateral Common Carotid Artery Occlusion.
BioMed research international , 2021 | Pubmed ID: 35005021
Retinal Disease and Metabolism.
Life (Basel, Switzerland) Jan, 2022 | Pubmed ID: 35207471
Ocular Ischemic Syndrome and Its Related Experimental Models.
International journal of molecular sciences May, 2022 | Pubmed ID: 35563640
À PROPOS DE JoVE
Copyright © 2024 MyJoVE Corporation. Tous droits réservés.